Elevated levels of the serine protease inhibitors SERPINB3 and SERPINB4 are seen in patients with atopic dermatitis and psoriasis, further clinical studies found that SERPINB4 is closely associated with the clinical severity of these two diseases. Here, SERPINB4 is linked to atopic eczema.